Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial.
Sawano F, Kamei N, Miyahara M, Kobuke K, Nakanishi S, Nagano C, Nojima H, Maeda S, Watanabe H, Kishimoto R, Yamashita M, Hamaoka A, Mukai K, Tsuboi T, Mochizuki H, Nakashima R, Sakashita Y, Morishita H, Kitamura T.
Sawano F, et al. Among authors: maeda s.
Diabetol Int. 2021 Feb 11;12(4):364-378. doi: 10.1007/s13340-021-00492-8. eCollection 2021 Oct.
Diabetol Int. 2021.
PMID: 34567919
Free PMC article.